Get the Stockscreener App
112.18
4.45%
4.78
Celcuity Inc stock is traded at $112.18, with a volume of 738.83K.
It is up +4.45% in the last 24 hours and up +4.27% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$107.40
Open:
$108.53
24h Volume:
738.83K
Relative Volume:
1.00
Market Cap:
$5.19B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-41.86
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+4.47%
1M Performance:
+4.27%
6M Performance:
+105.95%
1Y Performance:
+1,029%
1-Day Range:
$106.78
$112.50
1-Week Range:
$103.65
$113.41
52-Week Range:
$7.575
$120.31
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
112.18 | 4.97B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
CELC: Gedatolisib nears launch with strong trial data, regulatory momentum, and $10B+ peak potential - TradingView
TD Asset Management Inc Invests $3.60 Million in Celcuity, Inc. $CELC - MarketBeat
Artisan Partners Limited Partnership Boosts Stock Holdings in Celcuity, Inc. $CELC - MarketBeat
Celcuity Inc. (CELC) - DirectorsTalk Interviews
A Look At Celcuity (CELC) Valuation After Charles Romp Joins The Board And Gedatolisib Progress - simplywall.st
Celcuity To Participate in Upcoming Investor Conferences - The Manila Times
Celcuity Adds Oncology Veteran To Board As Gedatolisib Commercial Stakes Rise - Yahoo Finance
Bull Run: Should I set a stop loss on Celcuity IncJuly 2025 Opening Moves & Verified Swing Trading Watchlists - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (CELC) Movement - Stock Traders Daily
Is Celcuity’s (CELC) New Board Appointment a Turning Point for Its Commercial Strategy? - simplywall.st
Patient Square Capital LP Acquires Shares of 100,000 Celcuity, Inc. $CELC - MarketBeat
Soleus Adds a Significant Number of Celcuity Shares - AOL.com
Perceptive Advisors Increases Stake in Celcuity - Intellectia AI
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position - Yahoo Finance
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position - The Motley Fool
Avoro Capital Advisors LLC Acquires Significant Stake in Celcuit - GuruFocus
Avoro Capital Advisors LLC Acquires Significant Stake in Celcuity Inc - GuruFocus
Celcuity Inc. (CELC) Stock Analysis: Biotechnology Innovator’s 9.29% Upside Captures Investor Attention - DirectorsTalk Interviews
Celcuity, Inc. (NASDAQ:CELC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Decliners Report: How does Celcuity Inc correlate with Nasdaq2025 Buyback Activity & Fast Momentum Entry Tips - baoquankhu1.vn
What Celcuity (CELC)'s Board Addition of Veteran Oncology Executive Means For Shareholders - Yahoo Finance
Commit To Purchase Celcuity At $45, Earn 17.8% Using Options - Nasdaq
Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Soleus Capital Increases Stake in Celcuity - Intellectia AI
Is Celcuity’s New Oncology Commercial Leader Appointment Reshaping the Investment Case for CELC? - simplywall.st
Celcuity Adds Veteran Director to Strengthen Oncology Strategy - TipRanks
Ex-Seagen oncology exec joins Celcuity board for breast cancer drug push - Stock Titan
Discipline and Rules-Based Execution in CELC Response - Stock Traders Daily
Can Celcuity Inc. ride the EV waveJuly 2025 Outlook & Weekly Watchlist for Consistent Profits - mfd.ru
Celcuity CEO Sets July 17 PDUFA for Gedatolisib, Teases VIKTORIA-1 Mutant Data at Conference - MarketBeat
Celcuity at Guggenheim Summit: Biotech Innovations Unveiled By Investing.com - Investing.com Canada
CELC: Gedatolisib nears approval with strong efficacy, broad utility, and major commercial potential - TradingView
Candriam S.C.A. Increases Holdings in Celcuity, Inc. $CELC - MarketBeat
Celcuity, Inc. $CELC Stake Boosted by New York State Common Retirement Fund - MarketBeat
Inflation Data: Does Celcuity Inc align with a passive investing strategyJuly 2025 Pullbacks & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Published on: 2026-02-08 07:23:47 - baoquankhu1.vn
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump - The Globe and Mail
Wall Street Recap: Is Celcuity Inc stock a smart retirement pickGold Moves & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Profit Review: Can Celcuity Inc ride the EV wave2025 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
Assessing Celcuity (CELC) Valuation After Recent Share Price Momentum And DCF Upside Estimate - Yahoo Finance
Wolfe Research recommends buying Celcuity stock on weakness related to external catalyst By Investing.com - Investing.com South Africa
Wolfe Research recommends buying Celcuity stock on weakness related to external catalyst - Investing.com Nigeria
Biotech Stocks To ResearchFebruary 4th - MarketBeat
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Wealth Enhancement Advisory Services LLC Sells 10,476 Shares of Celcuity, Inc. $CELC - MarketBeat
Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances - Insider Monkey
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):